Biogen Inc.
Biogen Inc.（BIIB）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BIIB · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
4
近12个月
买卖比
0.25
Buy/Sell (by trades)
整体情绪
Biogen Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BIIB 季度内部人买卖趋势
BIIB 内幕交易卖出 · BIIB 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BIIB CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BIIB 高管卖出股份 · BIIB 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 1, 2026 | Keeney Adam Head of Corporate Development | Option | 939 | — | Form 4 |
| May 1, 2026 | Keeney Adam Head of Corporate Development | Other | 455 | $85K | Form 4 |
| Apr 1, 2026 | Godbout Sean CAO | Option | 181 | — | Form 4 |
| Apr 1, 2026 | Godbout Sean CAO | Other | 54 | $10K | Form 4 |
| Feb 12, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Purchase | 3 | $585 | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Option | 15,453 | — | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Other | 6,624 | $1.33M⚡ | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Option | 9,008 | — | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Other | 4,356 | $876K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Option | 4,683 | — | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Other | 1,412 | $284K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Option | 2,217 | — | Form 4 |
| Feb 9, 2026 | Singhal Priya Head of Development | Sale | 2,660 | $532K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Other | 1,056 | $212K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 4,683 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 1,408 | $283K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 1,940 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 914 | $184K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 2,102 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 1,017 | $205K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 3,511 | — | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Other | 1,063 | $214K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 703 | — | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Other | 207 | $42K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 789 | — | Form 4 |
Viehbacher Christopher
President and CEO · Director
日期
Feb 6
股数
15,453
均价
—
总金额
—
Viehbacher Christopher
President and CEO · Director
日期
Feb 6
股数
6,624
均价
$201.18
总金额
$1.33M ⚡
Viehbacher Christopher
President and CEO · Director
日期
Feb 6
股数
4,356
均价
$201.18
总金额
$876K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BIIB 内幕交易
BIIB 内幕交易
Biogen Inc.（BIIB）内幕交易数据来源于公司内部人（包括Godbout Sean (CAO), Singhal Priya (Head of Development), Murphy Nicole (Head of Pharm Ops and Tech)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BIIB内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Biogen Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BIIB 内幕交易 · 5个问题Biogen Inc.（BIIB）的内部人包括高管和董事，如Godbout Sean (CAO), Singhal Priya (Head of Development), Murphy Nicole (Head of Pharm Ops and Tech)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026